
H Gilbert Welch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4046627/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hospital Volume and Surgical Mortality in the United States. New England Journal of Medicine, 2002, 346, 1128-1137.	13.9	4,602
2	Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. JAMA - Journal of the American Medical Association, 2006, 295, 2164.	3.8	2,895
3	Overdiagnosis in Cancer. Journal of the National Cancer Institute, 2010, 102, 605-613.	3.0	1,392
4	Current Thyroid Cancer Trends in the United States. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 317.	1.2	1,334
5	The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence. Journal of the National Cancer Institute, 2005, 97, 142-146.	3.0	1,173
6	Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. New England Journal of Medicine, 2012, 367, 1998-2005.	13.9	1,119
7	Korea's Thyroid-Cancer "Epidemic―— Screening and Overdiagnosis. New England Journal of Medicine, 2014, 371, 1765-1767.	13.9	948
8	National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. Journal of Vascular Surgery, 2009, 50, 54-60.	0.6	615
9	Enthusiasm for Cancer Screening in the United States. JAMA - Journal of the American Medical Association, 2004, 291, 71.	3.8	607
10	Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy. New England Journal of Medicine, 1993, 328, 1237-1243.	13.9	523
11	Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. Journal of the National Cancer Institute, 2009, 101, 1325-1329.	3.0	508
12	Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine, 2016, 375, 1438-1447.	13.9	486
13	Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology, The, 2014, 15, e234-e242.	5.1	423
14	Surgical Mortality as an Indicator of Hospital Quality. JAMA - Journal of the American Medical Association, 2004, 292, 847.	3.8	413
15	Population-Based Risk for Complications After Transthoracic Needle Lung Biopsy of a Pulmonary Nodule: An Analysis of Discharge Records. Annals of Internal Medicine, 2011, 155, 137.	2.0	403
16	Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak?. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1468-1470.	1.1	399
17	Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer?. JAMA - Journal of the American Medical Association, 2000, 283, 2975.	3.8	365
18	Geographic Variation in Expenditures for Physicians' Services in the United States. New England Journal of Medicine, 1993, 328, 621-627.	13.9	360

#	Article	IF	CITATIONS
19	All-Cause Mortality in Randomized Trials of Cancer Screening. Journal of the National Cancer Institute, 2002, 94, 167-173.	3.0	325
20	Prudent Strategies for Elective Red Blood Cell Transfusion. Annals of Internal Medicine, 1992, 116, 393-402.	2.0	314
21	Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ: British Medical Journal, 2005, 331, 481.	2.4	282
22	Trends in the Use of the Pulmonary Artery Catheter in the United States, 1993-2004. JAMA - Journal of the American Medical Association, 2007, 298, 423-9.	3.8	278
23	Using Autopsy Series To Estimate the Disease "Reservoir―for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find?. Annals of Internal Medicine, 1997, 127, 1023.	2.0	273
24	Is language a barrier to the use of preventive services?. Journal of General Internal Medicine, 1997, 12, 472-477.	1.3	263
25	Estimating Treatment Benefits for the Elderly: The Effect of Competing Risks. Annals of Internal Medicine, 1996, 124, 577.	2.0	248
26	The Rapid Rise in Cutaneous Melanoma Diagnoses. New England Journal of Medicine, 2021, 384, 72-79.	13.9	224
27	Using a Drug Facts Box to Communicate Drug Benefits and Harms. Annals of Internal Medicine, 2009, 150, 516.	2.0	222
28	Avoiding the Unintended Consequences of Growth in Medical Care. JAMA - Journal of the American Medical Association, 1999, 281, 446.	3.8	212
29	The Natural History of Invasive Breast Cancers Detected by Screening Mammography. Archives of Internal Medicine, 2008, 168, 2311.	4.3	209
30	South Korea's Thyroid-Cancer "Epidemic―— Turning the Tide. New England Journal of Medicine, 2015, 373, 2389-2390.	13.9	194
31	Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?. Lancet, The, 2001, 358, 1141-1146.	6.3	182
32	Misunderstandings about the Effects of Race and Sex on Physicians' Referrals for Cardiac Catheterization. New England Journal of Medicine, 1999, 341, 279-283.	13.9	180
33	Quantifying the Benefits and Harms of Screening Mammography. JAMA Internal Medicine, 2014, 174, 448.	2.6	175
34	Colorectal Cancer on the Decline — Why Screening Can't Explain It All. New England Journal of Medicine, 2016, 374, 1605-1607.	13.9	170
35	Women's Perceptions of Breast Cancer Risk. Medical Decision Making, 1999, 19, 221-229.	1.2	164
36	Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics. New England Journal of Medicine, 2015, 373, 1685-1687.	13.9	161

#	Article	IF	CITATIONS
37	Detection of Prostate Cancer via Biopsy in the Medicare-SEER Population During the PSA Era. Journal of the National Cancer Institute, 2007, 99, 1395-1400.	3.0	160
38	The Use of Medicare Home Health Care Services. New England Journal of Medicine, 1996, 335, 324-329.	13.9	154
39	Breast Cancer Screening, Incidence, and Mortality Across US Counties. JAMA Internal Medicine, 2015, 175, 1483.	2.6	154
40	Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic Leukemia. New England Journal of Medicine, 1989, 321, 807-812.	13.9	150
41	The increasing incidence of small thyroid cancers: Where are the cases coming from?. Laryngoscope, 2010, 120, 2446-2451.	1.1	150
42	Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal. Journal of the National Cancer Institute, 2005, 97, 1132-1137.	3.0	143
43	Epidemiologic Signatures in Cancer. New England Journal of Medicine, 2019, 381, 1378-1386.	13.9	134
44	A New Scale for Assessing Perceptions of Chance. Medical Decision Making, 2000, 20, 298-307.	1.2	129
45	The frequency of Pap smear screening in the United States. Journal of General Internal Medicine, 2004, 19, 243-250.	1.3	127
46	Geographic Variation in Diagnosis Frequency and Risk of Death Among Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2011, 305, 1113.	3.8	127
47	The Cost of Institutional Care in Alzheimer's Disease: Nursing Home and Hospital Use in a Prospective Cohort. Journal of the American Geriatrics Society, 1992, 40, 221-224.	1.3	125
48	State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results. Pediatrics, 2006, 118, 448-456.	1.0	122
49	Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. American Journal of Medicine, 1993, 94, 509-514.	0.6	120
50	Reconsidering Prostate Cancer Mortality — The Future of PSA Screening. New England Journal of Medicine, 2020, 382, 1557-1563.	13.9	120
51	Saving Thyroids — Overtreatment of Small Papillary Cancers. New England Journal of Medicine, 2018, 379, 310-312.	13.9	115
52	Risk Charts: Putting Cancer in Context. Journal of the National Cancer Institute, 2002, 94, 799-804.	3.0	113
53	The Risk of Death by Age, Sex, and Smoking Status in the United States: Putting Health Risks in Context. Journal of the National Cancer Institute, 2008, 100, 845-853.	3.0	108
54	Screening Mammography — A Long Run for a Short Slide?. New England Journal of Medicine, 2010, 363, 1276-1278.	13.9	102

#	Article	IF	CITATIONS
55	The effectiveness of cost-effectiveness analysis in containing costs. Journal of General Internal Medicine, 1998, 13, 664-669.	1.3	101
56	The Drug Facts Box: Providing Consumers with Simple Tabular Data on Drug Benefit and Harm. Medical Decision Making, 2007, 27, 655-662.	1.2	101
57	Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy. JAMA Internal Medicine, 2018, 178, 221.	2.6	98
58	Physician Profiling An Analysis of Inpatient Practice Patterns in Florida and Oregon. New England Journal of Medicine, 1994, 330, 607-612.	13.9	94
59	Can Patients Interpret Health Information? An Assessment of the Medical Data Interpretation Test. Medical Decision Making, 2005, 25, 290-300.	1.2	93
60	A Comparison of the Educational Costs and Incomes of Physicians and Other Professionals. New England Journal of Medicine, 1994, 330, 1280-1286.	13.9	92
61	Dealing with Limited Resources. New England Journal of Medicine, 1988, 319, 171-173.	13.9	91
62	Regional Variations in Health Care Intensity and Physician Perceptions of Quality of Care. Annals of Internal Medicine, 2006, 144, 641.	2.0	91
63	Celebrity Endorsements of Cancer Screening. Journal of the National Cancer Institute, 2005, 97, 693-695.	3.0	78
64	Medicare Services Provided by Cardiologists in the United States: 1999–2008. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 31-36.	0.9	73
65	Cervical Cancer Screening Among Women Without a Cervix. JAMA - Journal of the American Medical Association, 2004, 291, 2990.	3.8	71
66	Machine Learning and the Cancer-Diagnosis Problem — No Gold Standard. New England Journal of Medicine, 2019, 381, 2285-2287.	13.9	69
67	Impact of Diastolic and Systolic Blood Pressure on Mortality: Implications for the Definition of "Normal― Journal of General Internal Medicine, 2011, 26, 685-690.	1.3	67
68	Association of Computed Tomographic Screening Promotion With Lung Cancer Overdiagnosis Among Asian Women. JAMA Internal Medicine, 2022, 182, 283.	2.6	62
69	Observational intensity bias associated with illness adjustment: cross sectional analysis of insurance claims. BMJ, The, 2013, 346, f549-f549.	3.0	61
70	Likelihood That a Woman With Screen-Detected Breast Cancer Has Had Her "Life Saved―by That Screening. Archives of Internal Medicine, 2011, 171, 2043.	4.3	60
71	Are Deaths Within 1 Month of Cancer-Directed Surgery Attributed to Cancer?. Journal of the National Cancer Institute, 2002, 94, 1066-1070.	3.0	59
72	Income and Cancer Overdiagnosis — When Too Much Care Is Harmful. New England Journal of Medicine, 2017, 376, 2208-2209.	13.9	56

#	Article	IF	CITATIONS
73	The Zero Mortality Paradox in Surgery. Journal of the American College of Surgeons, 2008, 206, 13-16.	0.2	51
74	Setting the revisit interval in primary care. Journal of General Internal Medicine, 1999, 14, 230-235.	1.3	49
75	Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. Obstetrical and Gynecological Survey, 2013, 68, 440-442.	0.2	49
76	The Effectiveness of a Primer to Help People Understand Risk. Annals of Internal Medicine, 2007, 146, 256.	2.0	48
77	Using the Results of a Baseline and a Surveillance Colonoscopy to Predict Recurrent Adenomas With High-Risk Characteristics. Annals of Internal Medicine, 2009, 151, 103.	2.0	48
78	Meeting walk-in patients' expectations for testing effects on satisfaction. Journal of General Internal Medicine, 1996, 11, 470-474.	1.3	47
79	Uncertainties in Genetic Testing for Chronic Disease. JAMA - Journal of the American Medical Association, 1998, 280, 1525-7.	3.8	46
80	Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ: British Medical Journal, 2006, 332, 727.1.	2.4	43
81	The Sea of Uncertainty Surrounding Ductal Carcinoma In SituThe Price of Screening Mammography. Journal of the National Cancer Institute, 2008, 100, 228-229.	3.0	43
82	Informed Choice in Cancer Screening. JAMA - Journal of the American Medical Association, 2001, 285, 2776.	3.8	40
83	Cancer Screening, Overdiagnosis, and Regulatory Capture. JAMA Internal Medicine, 2017, 177, 915.	2.6	38
84	Patients and medical statistics. Interest, confidence, and ability. Journal of General Internal Medicine, 2005, 20, 996-1000.	1.3	36
85	Teaching Evidence-based Medicine. Academic Medicine, 2000, 75, 235-240.	0.8	31
86	Scrutiny-Dependent Cancer and Self-fulfilling Risk Factors. Annals of Internal Medicine, 2018, 168, 143.	2.0	29
87	Health Care Tickets for the Uninsured. New England Journal of Medicine, 1989, 321, 1261-1264.	13.9	26
88	Repeated Upper Endoscopy in the Medicare Population. Annals of Internal Medicine, 2014, 160, 154.	2.0	26
89	Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Annals of Surgical Oncology, 2021, 28, 8688-8696.	0.7	25
90	Should the Health Care Forest Be Selectively Thinned by Physicians or Clear Cut by Payers?. Annals of Internal Medicine, 1991, 115, 223-226.	2.0	24

#	Article	IF	CITATIONS
91	Effect of Screening Mammography on Breast Cancer Incidence. New England Journal of Medicine, 2013, 368, 677-679.	13.9	22
92	Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA Dermatology, 2022, 158, 426.	2.0	22
93	The role of patients and providers in the timing of follow-up visits. Journal of General Internal Medicine, 1999, 14, 223-229.	1.3	21
94	Variation in Ultrasound Diagnostic Thresholds for Carotid Stenosis in the United States. Circulation, 2020, 141, 946-953.	1.6	19
95	Valuing Clinical Strategies Early in Their Development. Annals of Internal Medicine, 1992, 116, 263-264.	2.0	18
96	Risk for Increased Utilization and Adverse Health Outcomes among Men Served by the Veterans Health Administration. Military Medicine, 2007, 172, 690-696.	0.4	17
97	Patients Requiring at Least Five Admissions in 1 Year. Medical Care, 1991, 29, 578-582.	1.1	16
98	Rapid Estimation of Hospital Charges in Patients with Leukemia. Medical Care, 1989, 27, 900-904.	1.1	15
99	Evaluating Randomized Trials of Screening. Journal of General Internal Medicine, 1997, 12, 118-124.	1.3	15
100	Let's Make a Deal. New England Journal of Medicine, 1992, 327, 1312-1315.	13.9	13
101	Questions about the Value of Early Intervention. New England Journal of Medicine, 1996, 334, 1472-1473.	13.9	13
102	Tobacco money: up in smoke?. Lancet, The, 2002, 359, 2108-2111.	6.3	13
103	Breast-Cancer Tumor Size and Screening Effectiveness. New England Journal of Medicine, 2017, 376, 93-95.	13.9	13
104	Autologous bone marrrow transplantation versus chemotherapy in relapsed/refractory non-hodgkin's lymphoma: Estimates of long-term survival from the recent literatur. American Journal of Hematology, 1995, 50, 116-123.	2.0	12
105	Evaluating Randomized Trials of Screening. Journal of General Internal Medicine, 1997, 12, 118-124.	1.3	12
106	Physician Relations in Canada: Shooting Inward as the Circle Closes. Journal of Health Politics, Policy and Law, 1997, 22, 1413-1431.	0.9	12
107	Making the Call. JAMA - Journal of the American Medical Association, 2011, 306, 2649.	3.8	11
108	The heterogeneity of cancer. Breast Cancer Research and Treatment, 2018, 169, 207-208.	1.1	11

#	Article	IF	CITATIONS
109	Determining Transition Probabilities from Mortality Rates and Autopsy Findings. Medical Decision Making, 1997, 17, 87-93.	1.2	10
110	Right and Wrong Reasons To Be Screened. Annals of Internal Medicine, 2004, 140, 754.	2.0	8
111	Responding to the Challenge of Overdiagnosis. Academic Radiology, 2015, 22, 945-946.	1.3	8
112	Assessing Competing Risks in Treating the Elderly. Hospital Practice (1995), 1996, 31, 155-166.	0.5	7
113	Could More Health Care Lead to Worse Health?. Hospital Practice (1995), 1999, 34, 15-28.	0.5	7
114	Cancer Screening—The Good, the Bad, and the Ugly. JAMA Surgery, 2022, 157, 467.	2.2	7
115	Strategies in writing for a physician audience. Journal of General Internal Medicine, 1996, 11, 50-55.	1.3	6
116	Estimating the Impact of Adding C-Reactive Protein as a Criterion for Lipid Lowering Treatment in the United States. Journal of General Internal Medicine, 2007, 22, 197-204.	1.3	6
117	Not So Silver Lining. Archives of Internal Medicine, 2011, 171, 489-90.	4.3	5
118	Industry Payments to Physician Directors of National Cancer Institute–Designated Cancer Centers, 2015-2017. JAMA Internal Medicine, 2019, 179, 1595.	2.6	5
119	Rising Incidence of Cancer of the Small Intestine: Overdiagnosis and Better Diagnosis of Low-lethality Disease. Gastroenterology, 2022, 162, 1749-1751.e2.	0.6	5
120	Who's in charge here?. Journal of General Internal Medicine, 1994, 9, 450-454.	1.3	4
121	Stumbling onto Cancer: Avoiding Overdiagnosis of Renal Cell Carcinoma. American Family Physician, 2019, 99, 145-147.	0.1	4
122	A Markov model of early diagnosis. Academic Radiology, 1996, 3, S10-S12.	1.3	3
123	Should Recommendations for Cancer Screening Differentiate on Race?. , 2022, 1, .		3
124	In Zambia: Doing More with Less. Annals of Internal Medicine, 1983, 98, 551.	2.0	2
125	Davies and Welch Draw Unfounded Conclusions about Thyroid Cancer from Epidemiological Data—Reply. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 679.	1.2	2
126	Removing the Thyroid From Images, Not From Patients. JAMA Internal Medicine, 2020, 180, 896.	2.6	2

#	Article	IF	CITATIONS
127	Risk for Complications After Transthoracic Needle LungÂBiopsy. Annals of Internal Medicine, 2011, 155, 796.	2.0	2
128	Should We Screen Never-Smoking Asian Women for Lung Cancer Using Low-Dose Computed Tomography?—Reply. JAMA Internal Medicine, 2022, 182, 782.	2.6	2
129	Oregon??s Priority List???Pertinence to Radiologists. Investigative Radiology, 1992, 27, 379-384.	3.5	1
130	Who is Responsible for Care Given During the Inpatient Stay?. Medical Care, 1995, 33, 417-422.	1.1	1
131	ASO Visual Abstract: Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Annals of Surgical Oncology, 2021, 28, 545.	0.7	1
132	RESPONSE: Re: Risk Charts: Putting Cancer in Context. Journal of the National Cancer Institute, 2002, 94, 1585-1586.	3.0	0
133	Preparing Manuscripts for Submission to Medical Journals: The Paper Trail. Spine, 2004, 29, E442-E449.	1.0	0
134	Response to Strong. Genetics in Medicine, 2015, 17, 682-683.	1.1	0
135	Microscopic Screening of Reduction Mammoplasties Risks Overdiagnosis. Archives of Pathology and Laboratory Medicine, 2018, 142, 287-287.	1.2	0
136	Disclose and Manage Conflicts of Interest at Cancer Centers—Reply. JAMA Internal Medicine, 2020, 180, 161.	2.6	0
137	Continuous Physiologic Monitoring: False Alarms and Overdiagnosis. Journal of Hospital Medicine, 2018, 13, 431-432.	0.7	Ο